Gergely Huszty, László Bihari, László Gráf, Attila Szijártó, Szabolcs Máté
Peritoneal carcinosis has historically been considered as inoperable, although the technique of its resesection together with high dose intraperitoneal chemotherapy potentiated by heat has been described decades ago. It has not became a widely practiced routine except in specialized centers - the complex technique, weakly standardized but resource demanding chemotherapy, lacking financial background and the many times questionable clinical benefit at a cost of high surgical load might have been the key factors. Refined technology, developing chemotherapy protocols together with growing clinical evidence are now more sharply delineating the range of indications where the procedure might be beneficial, increases survival, or is the only curative therapy. These include tumors of the appendix and pseudomyxoma peritonei, mesothelioma, and selected cases of ovarian, colorectal and gastric cancer. In addition to technical description of the intervention, we summarize the currently valid indications and describe our institutional protocol for the treatment of appendiceal malignancies.
{"title":"[Surgery of peritoneal surface malignancies - surgical cytoreduction and hyperthermic intraperitoneal chemotherapy].","authors":"Gergely Huszty, László Bihari, László Gráf, Attila Szijártó, Szabolcs Máté","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Peritoneal carcinosis has historically been considered as inoperable, although the technique of its resesection together with high dose intraperitoneal chemotherapy potentiated by heat has been described decades ago. It has not became a widely practiced routine except in specialized centers - the complex technique, weakly standardized but resource demanding chemotherapy, lacking financial background and the many times questionable clinical benefit at a cost of high surgical load might have been the key factors. Refined technology, developing chemotherapy protocols together with growing clinical evidence are now more sharply delineating the range of indications where the procedure might be beneficial, increases survival, or is the only curative therapy. These include tumors of the appendix and pseudomyxoma peritonei, mesothelioma, and selected cases of ovarian, colorectal and gastric cancer. In addition to technical description of the intervention, we summarize the currently valid indications and describe our institutional protocol for the treatment of appendiceal malignancies.</p>","PeriodicalId":94127,"journal":{"name":"Magyar onkologia","volume":"67 3","pages":"247-258"},"PeriodicalIF":0.0,"publicationDate":"2023-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41180798","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Laura Vízkeleti, Andrea Ladányi, Orsolya Papp, Viktória Doma, Sarolta Kárpáti, Erzsébet Rásó, Tamás Barbai, József Tímár
We have followed the genomic progression of cutaneous melanoma in visceral metastases using genome-wide copy number analysis. We have detected an increased chromosomal instability due to the loss of several DNA repair genes. Furthermore, we found co-amplifications of HGF and MET genes in metastases. The most interesting finding was gene amplifications of several, mostly IFN-regulated immune cell genes in lung metastases. Next we have defined a type I IFN resistance gene expression signature (GES) using human cell lines, several elements of which were proved to be stable in vitro and in vivo as well. The components of this GES have been detected in TCGA as well as in publicly available datasets of immunotherapy-treated melanoma cases. In case of samples from previously IFN-treated melanoma cases we have identified treatment-specific genomic alterations (predominantly amplifications) which were most characteristic for brain metastases.
我们通过全基因组拷贝数分析，跟踪了内脏转移的皮肤黑色素瘤的基因组进展。我们发现，由于多个 DNA 修复基因的缺失，染色体不稳定性增加。此外，我们还在转移灶中发现了 HGF 和 MET 基因的共同扩增。最有趣的发现是肺转移瘤中几个主要由 IFN 调控的免疫细胞基因扩增。接下来，我们利用人体细胞系定义了 IFN 抗性基因表达特征（GES），其中几个元素在体外和体内都被证明是稳定的。在 TCGA 和公开的免疫疗法治疗黑色素瘤病例数据集中都检测到了这一 GES 的成分。在曾接受过 IFN 治疗的黑色素瘤病例样本中，我们发现了治疗特异性基因组改变（主要是扩增），这是脑转移瘤的最大特征。
{"title":"[Potential role of type I interferon in the genetic progression of melanoma].","authors":"Laura Vízkeleti, Andrea Ladányi, Orsolya Papp, Viktória Doma, Sarolta Kárpáti, Erzsébet Rásó, Tamás Barbai, József Tímár","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>We have followed the genomic progression of cutaneous melanoma in visceral metastases using genome-wide copy number analysis. We have detected an increased chromosomal instability due to the loss of several DNA repair genes. Furthermore, we found co-amplifications of HGF and MET genes in metastases. The most interesting finding was gene amplifications of several, mostly IFN-regulated immune cell genes in lung metastases. Next we have defined a type I IFN resistance gene expression signature (GES) using human cell lines, several elements of which were proved to be stable in vitro and in vivo as well. The components of this GES have been detected in TCGA as well as in publicly available datasets of immunotherapy-treated melanoma cases. In case of samples from previously IFN-treated melanoma cases we have identified treatment-specific genomic alterations (predominantly amplifications) which were most characteristic for brain metastases.</p>","PeriodicalId":94127,"journal":{"name":"Magyar onkologia","volume":"67 3","pages":"215-221"},"PeriodicalIF":0.0,"publicationDate":"2023-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142577250","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Marcell Baranyi, Balázs Hegedűs, Eszter Molnár, József Tóvári, Ivan Ranđelović, András Perczel, László Buday, György Keserű, József Tímár
In silico studies raised the possibility that farnesyltransferase inhibitors (FTIs) may have antitumoral effects on KRAS mutant cancer cells. Accordingly, we have tested FTIs (tipifarnib and lonafarnib) in G12C mutant human cancer cell lines in vitro and in vivo. We have discovered that the combination of the two drugs has a synergistic antitumoral effect. Next, we have tested FTIs on G12D mutant human cancer cell lines and found that the combination has antitumoral effect in various preclinical cancer models. At last, we have also tested FTIs on G12V mutant human cancer cells and again we have detected antitumoral effects. We suggest that FTIs may have clinical relevance outside the HRAS mutant cancers.
{"title":"[Farnesyltransferase inhibitors have antitumoral effects in mutant KRAS containing cancer cells in preclinical models].","authors":"Marcell Baranyi, Balázs Hegedűs, Eszter Molnár, József Tóvári, Ivan Ranđelović, András Perczel, László Buday, György Keserű, József Tímár","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>In silico studies raised the possibility that farnesyltransferase inhibitors (FTIs) may have antitumoral effects on KRAS mutant cancer cells. Accordingly, we have tested FTIs (tipifarnib and lonafarnib) in G12C mutant human cancer cell lines in vitro and in vivo. We have discovered that the combination of the two drugs has a synergistic antitumoral effect. Next, we have tested FTIs on G12D mutant human cancer cell lines and found that the combination has antitumoral effect in various preclinical cancer models. At last, we have also tested FTIs on G12V mutant human cancer cells and again we have detected antitumoral effects. We suggest that FTIs may have clinical relevance outside the HRAS mutant cancers.</p>","PeriodicalId":94127,"journal":{"name":"Magyar onkologia","volume":"67 3","pages":"223-235"},"PeriodicalIF":0.0,"publicationDate":"2023-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140133677","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号